siRNA 의약품 시장 보고서 : 동향, 예측, 경쟁 분석(-2031년)

The future of the global siRNA drug market looks promising with opportunities in the hospital, research institute, and pharmaceutical & biotechnology company markets. The global siRNA drug market is expected to grow with a CAGR of 19.4% from 2025 to 2031. The major drivers for this market are the increasing prevalence of genetic disorders, the rising demand for personalized medicine, and the growing focus on RNA-based therapies.

• Lucintel forecasts that, within the delivery method category, nanoparticle is expected to witness the highest growth over the forecast period.
• Within the end use category, hospital is expected to witness the highest growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the siRNA Drug Market

The siRNA drug market is experiencing rapid growth driven by advances in gene silencing technology, increasing demand for targeted therapies, and a deeper understanding of genetic diseases. As research progresses, the market is characterized by innovation, strategic collaborations, and expanding applications across various therapeutic areas. These developments are transforming the landscape of personalized medicine and offering new hope for previously untreatable conditions. The following key trends highlight the major shifts shaping this dynamic market, reflecting technological, regulatory, and commercial advancements that are paving the way for future growth and improved patient outcomes.

• Growing Investment in Research and Development: Increased funding from biotech firms, pharmaceutical companies, and government agencies is accelerating siRNA technology development. This investment supports the discovery of novel delivery systems, enhanced stability, and specificity of siRNA molecules. As R&D efforts intensify, more effective and safe siRNA-based therapies are emerging, reducing time-to-market and expanding the pipeline of potential drugs. This trend underscores a commitment to overcoming current limitations and unlocking the full therapeutic potential of siRNA technology.
• Advances in Delivery Technologies: The development of innovative delivery systems such as lipid nanoparticles, conjugates, and viral vectors is crucial for effective siRNA therapy. These advancements improve cellular uptake, stability, and targeted delivery, minimizing off-target effects and toxicity. Enhanced delivery methods are enabling siRNA drugs to reach previously inaccessible tissues and organs, broadening their therapeutic applications. This trend is pivotal in overcoming one of the main challenges in siRNA therapeutics, thereby increasing clinical success rates and market adoption.
• Expansion into New Therapeutic Areas: Initially focused on genetic disorders and cancer, siRNA drugs are now being explored for infectious diseases, rare diseases, and inflammatory conditions. This diversification is driven by the versatility of siRNA technology to silence specific genes involved in various pathologies. As new indications are identified, the market is expanding, attracting more investment and regulatory interest. This trend is making siRNA therapies more comprehensive and personalized, addressing unmet medical needs across a broader spectrum of diseases.
• Increasing Strategic Collaborations and Partnerships: Collaborations between biotech firms, pharmaceutical companies, and academic institutions are becoming more prevalent. These partnerships facilitate knowledge sharing, resource pooling, and accelerated development timelines. Licensing agreements and joint ventures are also common, helping to navigate regulatory pathways and commercialize products efficiently. Such collaborations are vital for overcoming technical challenges and bringing innovative siRNA therapies to market faster, ultimately boosting market growth and competitiveness.
• Evolving Regulatory Landscape: Regulatory agencies are developing specific guidelines for siRNA-based therapies, which influence market entry strategies. Clearer regulatory pathways and approval processes are reducing uncertainties and encouraging investment. However, regulatory challenges related to safety, delivery, and off-target effects remain. Ongoing dialogue between developers and regulators is essential to establish standards that ensure safety while fostering innovation. This evolving landscape is shaping the pace of market expansion and influencing strategic planning for companies operating in this space.

In summary, these trends are collectively reshaping the siRNA drug market by fostering innovation, expanding therapeutic possibilities, and streamlining development processes. They are driving the market toward more effective, targeted, and personalized treatments, ultimately improving patient outcomes and opening new commercial opportunities. As these developments continue, the siRNA market is poised for significant growth and increased impact in the healthcare industry.

Recent Developments in the siRNA Drug Market

The siRNA drug market has experienced significant growth driven by advancements in gene silencing technologies, increasing investment in biotech research, and a rising demand for targeted therapies. As precision medicine gains prominence, the development of siRNA-based treatments offers promising solutions for various diseases, including genetic disorders, cancers, and viral infections. Recent innovations and strategic collaborations have accelerated the pipeline of siRNA drugs, making them more effective and accessible. These developments are reshaping the landscape of personalized medicine, fostering new opportunities for pharmaceutical companies, and expanding the therapeutic potential of siRNA technology globally.

• Technological Advancements: Enhanced delivery systems such as lipid nanoparticles and conjugates have improved siRNA stability and targeting accuracy, leading to higher efficacy and reduced side effects, thus broadening the scope of clinical applications.
• Strategic Collaborations: Major biotech firms and pharmaceutical companies are forming partnerships to accelerate research and development, share expertise, and streamline regulatory approvals, which is speeding up the commercialization of siRNA drugs.
• Regulatory Approvals: Recent approvals of siRNA-based therapies, such as those for hereditary transthyretin amyloidosis, have validated the technology and increased investor confidence, encouraging further innovation and market entry.
• Expanding Therapeutic Areas: Researchers are exploring siRNA applications beyond genetic disorders, including cancer, infectious diseases, and rare conditions, thereby diversifying the market and increasing revenue streams.
• Investment and Funding: Rising investments from venture capitalists and government agencies are fueling innovation, supporting clinical trials, and facilitating the scaling of manufacturing processes, which collectively boost market growth.

These developments are significantly impacting the siRNA drug market by enhancing drug efficacy, expanding therapeutic options, and attracting increased investment. The market is becoming more competitive and innovative, leading to faster drug development cycles and broader patient access. Overall, these trends are positioning siRNA technology as a cornerstone of future personalized medicine, promising improved health outcomes and substantial commercial opportunities.

Strategic Growth Opportunities in the siRNA Drug Market

The siRNA drug market is experiencing rapid growth driven by advancements in gene silencing technology and increasing demand for targeted therapies. As precision medicine gains prominence, the market is expanding across various applications, including oncology, infectious diseases, genetic disorders, respiratory diseases, and rare diseases. These applications are unlocking new therapeutic possibilities, attracting investments, and fostering innovation. The evolving landscape presents significant opportunities for pharmaceutical companies, biotech firms, and research institutions to develop novel siRNA-based solutions. Understanding these key growth opportunities is essential for stakeholders aiming to capitalize on the markets potential and address unmet medical needs effectively.

• Targeted Cancer Therapies: siRNA enables precise silencing of oncogenes, improving treatment efficacy and reducing side effects, thus transforming cancer management.
• Antiviral and Antimicrobial Agents: siRNA offers a promising approach to combat resistant pathogens by silencing essential viral or microbial genes, enhancing infectious disease control.
• Personalized Medicine: siRNA facilitates gene-specific interventions for hereditary conditions, providing tailored treatments that improve patient outcomes.
• Asthma and COPD Management: siRNA-based therapies can modulate inflammatory pathways, offering new options for chronic respiratory conditions.
• Orphan Drug Development: siRNA provides a novel therapeutic avenue for rare genetic disorders, addressing unmet needs and expanding market opportunities.

In summary, these growth opportunities are significantly impacting the siRNA drug market by broadening its application scope, fostering innovation, and attracting investments. They are driving the development of targeted, effective therapies that meet diverse medical needs, ultimately accelerating market expansion and improving patient care outcomes.

siRNA Drug Market Driver and Challenges

The siRNA drug market is influenced by a complex interplay of technological advancements, economic factors, and regulatory frameworks. Rapid innovations in gene-silencing technologies have opened new therapeutic avenues, while economic considerations such as R&D investments and healthcare spending impact market growth. Additionally, regulatory policies governing drug approval and safety standards significantly shape market dynamics. These factors collectively determine the pace of market expansion, the development of new treatments, and the challenges faced by industry stakeholders. Understanding these drivers and challenges is essential for strategic planning and sustainable growth in the evolving landscape of siRNA therapeutics.

The factors responsible for driving the siRNA drug market include:-

• Technological Innovation: The continuous development of more efficient delivery systems and enhanced stability of siRNA molecules has significantly propelled market growth. Advances such as lipid nanoparticles and conjugation techniques improve targeting accuracy and reduce side effects, making siRNA drugs more viable for clinical use. These innovations enable the development of personalized medicine and expand the scope of treatable diseases, including genetic disorders and cancers. As research progresses, the pipeline of potential therapies grows, attracting investments and fostering market expansion.
• Rising Prevalence of Chronic Diseases: The increasing incidence of chronic and genetic diseases such as cancer, hepatitis, and rare genetic disorders drives demand for targeted therapies like siRNA drugs. These conditions often lack effective treatments, creating a significant need for innovative solutions. The ability of siRNA to selectively silence disease-causing genes offers a promising therapeutic approach, encouraging pharmaceutical companies to invest in research and development. This trend is expected to sustain market growth as unmet medical needs continue to rise globally.
• Regulatory Approvals and Support: Favorable regulatory pathways and approvals for siRNA-based therapies have accelerated market penetration. Regulatory agencies are increasingly recognizing the potential of RNA interference technology, providing guidelines that facilitate clinical trials and commercialization. Supportive policies, grants, and collaborations between biotech firms and regulatory bodies further streamline the development process. These factors reduce time-to-market and boost investor confidence, thereby fueling market expansion.
• Strategic Collaborations and Investments: Partnerships between biotech firms, pharmaceutical companies, and academic institutions have been instrumental in advancing siRNA research. These collaborations facilitate resource sharing, accelerate clinical development, and enhance technological capabilities. Increased venture capital investments and funding initiatives also support innovation and commercialization efforts. Such strategic alliances help overcome technical challenges and expand the pipeline of siRNA drugs, contributing to sustained market growth.

The challenges facing this siRNA drug market include:-

• Delivery and Stability Issues: One of the primary challenges in the siRNA drug market is ensuring efficient delivery to target cells while maintaining stability in the bloodstream. siRNA molecules are prone to degradation by nucleases, and their large size hampers cellular uptake. Developing safe, effective delivery systems such as lipid nanoparticles or conjugates adds complexity and cost to drug development. Overcoming these hurdles is crucial for clinical success and widespread adoption, but technical limitations continue to impede rapid progress.
• Off-Target Effects and Safety Concerns: siRNA therapies may inadvertently silence unintended genes, leading to off-target effects that can cause adverse reactions. Ensuring specificity and minimizing immune responses remain significant challenges. Regulatory agencies demand rigorous safety data, which prolongs development timelines and increases costs. Addressing these safety concerns is vital for gaining regulatory approval and market acceptance, but the complexity of gene regulation complicates this process.
• High Development Costs and Lengthy Approval Processes: The cost of developing siRNA drugs is substantial due to extensive research, clinical trials, and regulatory compliance. The lengthy approval process delays market entry and increases financial risks for companies. Limited manufacturing scalability and high production costs further hinder commercialization. These economic barriers restrict the entry of smaller players and slow overall market growth, despite the promising therapeutic potential.

In summary, the siRNA drug market is driven by technological innovations, increasing disease prevalence, regulatory support, and strategic collaborations. However, challenges such as delivery issues, safety concerns, and high development costs pose significant hurdles. These factors collectively influence the pace of market growth, requiring ongoing innovation and regulatory navigation. Overcoming these challenges will be essential for realizing the full potential of siRNA therapeutics and achieving sustainable market expansion in the coming years.

List of siRNA Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies siRNA drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the siRNA drug companies profiled in this report include-

• Alnylam Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals, Inc.
• Silence Therapeutics plc
• Dicerna Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.
• Arbutus Biopharma Corporation
• Benitec Biopharma Ltd.
• Marina Biotech, Inc.
• Quark Pharmaceuticals, Inc.
• RXi Pharmaceuticals Corporation

siRNA Drug Market by Segment

The study includes a forecast for the global siRNA drug market by delivery method, application, end use, and region.

siRNA Drug Market by Delivery Method [Value from 2019 to 2031]:

• Nanoparticles
• Lipid-based
• Polymer-based
• Others

siRNA Drug Market by Application [Value from 2019 to 2031]:

• Oncology
• Cardiovascular
• Respiratory
• Neurological
• Infectious Diseases
• Others

siRNA Drug Market by End Use [Value from 2019 to 2031]:

• Hospitals
• Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others

siRNA Drug Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the siRNA Drug Market

The siRNA drug market has experienced significant growth driven by advancements in gene therapy, increasing investment in biotech research, and a rising demand for targeted treatments for various diseases. As precision medicine gains traction, countries are focusing on innovative delivery systems, regulatory approvals, and expanding clinical trials. The competitive landscape is evolving with collaborations between biotech firms and pharmaceutical giants, aiming to accelerate the development and commercialization of siRNA-based therapies. These developments reflect a global shift towards personalized medicine, with each country contributing uniquely based on its research capabilities, regulatory environment, and healthcare priorities.

• United States: The US leads in siRNA drug development with numerous clinical trials underway, driven by major biotech companies like Alnylam and Moderna. Regulatory agencies have approved several siRNA therapies, which have boosted market confidence. Investment in research and partnerships with academic institutions is accelerating innovation, especially in rare diseases and genetic disorders. The US also sees increased commercialization efforts and expanding manufacturing capabilities to meet rising demand.
• China: China is rapidly advancing in siRNA research, supported by government initiatives and increased funding for biotech startups. Several local companies are entering clinical trials, focusing on cancer and infectious diseases. The country is also developing its manufacturing infrastructure to reduce reliance on imports and improve cost competitiveness. Regulatory frameworks are evolving to facilitate faster approval processes, encouraging domestic innovation.
• Germany: Germany emphasizes precision medicine and has a strong biotech research ecosystem. Several startups and established firms are conducting clinical trials for siRNA therapies targeting neurological and metabolic diseases. The country benefits from collaborations within the European Union, facilitating access to funding and regulatory support. Germany is also investing in advanced delivery technologies to enhance siRNA efficacy and safety.
• India: India is emerging as a key player in siRNA research, with increasing government and private sector investments. Several research institutions are conducting early-stage trials, focusing on infectious diseases and cancer. The country aims to develop affordable therapies by building local manufacturing capacity and reducing costs. Regulatory reforms are underway to streamline approval processes and promote innovation in gene-based therapies.
• Japan: Japan is focusing on integrating siRNA therapies into its healthcare system, with significant investments in research and development. The country has established collaborations between academia and industry to accelerate clinical trials, especially for rare and genetic diseases. Japan is also advancing delivery technologies and exploring combination therapies to improve treatment outcomes. Regulatory pathways are being refined to support faster market entry for innovative siRNA drugs.

Features of the Global siRNA Drug Market

• Market Size Estimates: siRNA drug market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: siRNA drug market size by delivery method, application, end use, and region in terms of value ($B).
• Regional Analysis: siRNA drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different delivery method, application, end use, and regions for the siRNA drug market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the siRNA drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the siRNA drug market by delivery method (nanoparticles, lipid-based, polymer-based, and others), application (oncology, cardiovascular, respiratory, neurological, infectious diseases, and others), end use (hospitals, research institutes, pharmaceutical & biotechnology companies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global siRNA Drug Market by Delivery Method

• 4.1 Overview
• 4.2 Attractiveness Analysis by Delivery Method
• 4.3 Nanoparticles : Trends and Forecast (2019-2031)
• 4.4 Lipid-based : Trends and Forecast (2019-2031)
• 4.5 Polymer-based : Trends and Forecast (2019-2031)
• 4.6 Others : Trends and Forecast (2019-2031)

5. Global siRNA Drug Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Oncology : Trends and Forecast (2019-2031)
• 5.4 Cardiovascular : Trends and Forecast (2019-2031)
• 5.5 Respiratory : Trends and Forecast (2019-2031)
• 5.6 Neurological : Trends and Forecast (2019-2031)
• 5.7 Infectious Diseases : Trends and Forecast (2019-2031)
• 5.8 Others : Trends and Forecast (2019-2031)

6. Global siRNA Drug Market by End Use

• 6.1 Overview
• 6.2 Attractiveness Analysis by End Use
• 6.3 Hospitals : Trends and Forecast (2019-2031)
• 6.4 Research Institutes : Trends and Forecast (2019-2031)
• 6.5 Pharmaceutical & Biotechnology Companies : Trends and Forecast (2019-2031)
• 6.6 Others : Trends and Forecast (2019-2031)

7. Regional Analysis

• 7.1 Overview
• 7.2 Global siRNA Drug Market by Region

8. North American siRNA Drug Market

• 8.1 Overview
• 8.2 North American siRNA Drug Market by Delivery Method
• 8.3 North American siRNA Drug Market by End Use
• 8.4 The United States siRNA Drug Market
• 8.5 Canadian siRNA Drug Market
• 8.6 Mexican siRNA Drug Market

9. European siRNA Drug Market

• 9.1 Overview
• 9.2 European siRNA Drug Market by Delivery Method
• 9.3 European siRNA Drug Market by End Use
• 9.4 German siRNA Drug Market
• 9.5 French siRNA Drug Market
• 9.6 Italian siRNA Drug Market
• 9.7 Spanish siRNA Drug Market
• 9.8 The United Kingdom siRNA Drug Market

10. APAC siRNA Drug Market

• 10.1 Overview
• 10.2 APAC siRNA Drug Market by Delivery Method
• 10.3 APAC siRNA Drug Market by End Use
• 10.4 Chinese siRNA Drug Market
• 10.5 Indian siRNA Drug Market
• 10.6 Japanese siRNA Drug Market
• 10.7 South Korean siRNA Drug Market
• 10.8 Indonesian siRNA Drug Market

11. ROW siRNA Drug Market

• 11.1 Overview
• 11.2 ROW siRNA Drug Market by Delivery Method
• 11.3 ROW siRNA Drug Market by End Use
• 11.4 Middle Eastern siRNA Drug Market
• 11.5 South American siRNA Drug Market
• 11.6 African siRNA Drug Market

12. Competitor Analysis

• 12.1 Product Portfolio Analysis
• 12.2 Operational Integration
• 12.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 12.4 Market Share Analysis

13. Opportunities & Strategic Analysis

• 13.1 Value Chain Analysis
• 13.2 Growth Opportunity Analysis
  • 13.2.1 Growth Opportunity by Delivery Method
  • 13.2.2 Growth Opportunity by Application
  • 13.2.3 Growth Opportunity by End Use
• 13.3 Emerging Trends in the Global siRNA Drug Market
• 13.4 Strategic Analysis
  • 13.4.1 New Product Development
  • 13.4.2 Certification and Licensing
  • 13.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

14. Company Profiles of the Leading Players Across the Value Chain

• 14.1 Competitive Analysis Overview
• 14.2 Alnylam Pharmaceuticals, Inc.
  • Company Overview
  • siRNA Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.3 Arrowhead Pharmaceuticals, Inc.
  • Company Overview
  • siRNA Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.4 Silence Therapeutics plc
  • Company Overview
  • siRNA Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.5 Dicerna Pharmaceuticals, Inc.
  • Company Overview
  • siRNA Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.6 Ionis Pharmaceuticals, Inc.
  • Company Overview
  • siRNA Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.7 Arbutus Biopharma Corporation
  • Company Overview
  • siRNA Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.8 Benitec Biopharma Ltd.
  • Company Overview
  • siRNA Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.9 Marina Biotech, Inc.
  • Company Overview
  • siRNA Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.10 Quark Pharmaceuticals, Inc.
  • Company Overview
  • siRNA Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.11 RXi Pharmaceuticals Corporation
  • Company Overview
  • siRNA Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

15. Appendix

• 15.1 List of Figures
• 15.2 List of Tables
• 15.3 Research Methodology
• 15.4 Disclaimer
• 15.5 Copyright
• 15.6 Abbreviations and Technical Units
• 15.7 About Us
• 15.8 Contact Us